VitaDX: Artificial intelligence dedicated to the early detection of cancers Using image processing and machine learning algorithms, VitaDX, based on fluorescence imaging research at the Orsay Institute of Molecular Sciences, will automate early bladder cancer detection.
Thursday June 15th, 2017
Tuesday June 13th, 2017
VitaDX quoted in Les Echos for its second fundraising: "VitaDX wants to strengthen the early diagnosis of bladder cancer"
Monday June 12th, 2017
VitaDX is very pleased to announce the signing of a partnership with Cerba Healthcare as part of the validation of the VisioCyt® test for early diagnosis of bladder cancer.
Tuesday June 6th, 2017
VitaDX has just closed its second fundraising € 1.6 million with two investment funds Go Capital and Auriga Partners as well as private investors.
Monday May 15th, 2017
TOP 20 HEALTH START-UP - VitaDX detects early bladder cancer: The company has developed an algorithm capable of detecting bladder cancer at an early stage from a simple urine sample.
Monday May 1st, 2017
Friday April 28th, 2017
Allan Rodriguez, CEO of VitaDX and Xavier Apolinarski, President of the SATT Paris-Saclay, signed on the 26 April 2017 a contract sealing the collaboration between VitaDX, SATT Paris-Saclay and the French Aerospace Lab (ONERA).
Monday April 24th, 2017
Monday April 10th, 2017
VitaDX is among the top french Medtech startups to follow in 2017 according to AlloWeb.org !
Monday March 6th, 2017
TV Interview of Professor Thierry Lebret, Head of the Urology at the Foch Hospital in Suresnes and President of the French Association of Urology (AFU), during « Training thursdays » hosted by Jean-François Lemoine on Fréquence Médicale.